The field of pediatrics has been acknowledged since early eras, comprising references from the works of Hippocrates. Children are prone to a number of diseases like adults, frequently leading to clinical treatment that uses the same drugs and biological products. Use of medications in children has a long and storied past from exposure to tetanus tainted diphtheria toxin, through the sulfanilamide pediatric formulation tragedy and the in utero exposure to thalidomide. Each of these misfortunes caused in legislation to encourage the development of safe and efficacious therapeutics. Even though the level of applicable investigation has been growing, only a fraction of the obtainable treatments in adults have been sufficiently evaluated in pediatric populations to assess age-appropriate dosing, tolerability, and efficacy.
HTML PDFShare this article
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report
